Product Description
Mechanisms of Action: TXA2 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous,Oral,Ophthalmic
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: China | India | Korea | Pakistan
Approved Indications: None
Known Adverse Events: None
Company: Kissei Co
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Ischemic Stroke
Phase 3: Keratoconjunctivitis Sicca|Sjogren's Syndrome|Dry Eye Syndromes
Phase 2: Dry Eye Syndromes|Keratoconjunctivitis Sicca
Phase 1: Chronic Obstructive Pulmonary Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| KCT1303 | P3 |
Completed |
Dry Eye Syndromes|Keratoconjunctivitis Sicca|Sjogren's Syndrome |
2017-10-19 |
|
| KCT1302 | P3 |
Terminated |
Keratoconjunctivitis Sicca|Sjogren's Syndrome|Dry Eye Syndromes |
2017-05-29 |
24% |
| KCT1301 | P3 |
Completed |
Keratoconjunctivitis Sicca|Dry Eye Syndromes|Sjogren's Syndrome |
2017-01-01 |
|
| KCT1205 | P2 |
Completed |
Keratoconjunctivitis Sicca|Dry Eye Syndromes |
2014-03-01 |